Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + liposomal irinotecan + 5-fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Sanjun Cai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This combination regimen is a multi-agent chemotherapy and targeted therapy protocol consisting of bevacizumab, liposomal irinotecan, 5-fluorouracil (5-FU), and leucovorin. It is currently being investigated in the Phase II IRIS trial (NCT06184698) as a second-line treatment for patients with metastatic colorectal cancer who have progressed on oxaliplatin-based first-line therapy. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis. Liposomal irinotecan is a nanoliposomal formulation of the topoisomerase I inhibitor irinotecan, designed to enhance drug delivery to tumor tissues while reducing systemic toxicity. 5-FU is an antimetabolite that inhibits thymidylate synthase, and leucovorin is administered to potentiate the cytotoxic effects of 5-FU. Preliminary clinical data suggest that this combination offers encouraging activity with a manageable safety profile in the advanced colorectal cancer setting.
- Brand names
- Duoenda
- Other names
- bevacizumab + irinotecan liposome + 5-FU/LVbevacizumab + nal-IRI + 5-FU/LV
02
Targets
Beyond the preview
Go deeper on bevacizumab + liposomal irinotecan + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + liposomal irinotecan + 5-fluorouracil + leucovorin.